Meeting
2014 ASCO Annual Meeting
Longer-term follow up of a phase 1 study of ponatinib in patients (pts) with Philadelphia chromosome-positive (Ph+) leukemias.
Authors
Moshe Talpaz
Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI
Moshe Talpaz , Jorge E. Cortes , Hagop M. Kantarjian , Neil P. Shah , Dale L. Bixby , Ian Flinn , Thomas O'Hare , Simin Hu , Victor M. Rivera , Tim Clackson , Christopher D. Turner , Frank G. Haluska , Brian J Drucker , Michael W.N. Deininger , Michael J. Mauro
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Leukemia, Myelodysplasia, and Transplantation
Track
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant
Sub Track
Leukemia
Clinical Trial Registration Number
NCT00660920
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 7078)
DOI
10.1200/jco.2014.32.15_suppl.7078
Abstract #
7078
Poster Bd #
363
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
4-year results of the ponatinib phase II PACE trial in patients (pts) with heavily pretreated leukemia.
First Author: Jorge E. Cortes
First Author: Ronald J. Rieder
Poster
2016 ASCO Annual Meeting
Updated results from phase II study of combination of hyper-CVAD (HCVAD) with ponatinib in frontline therapy of patients (pts) with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
First Author: Koji Sasaki
Poster
2016 ASCO Annual Meeting
Phase I study of BP1001 (Liposomal Grb2 Antisense) in patients with hematologic malignancies.
First Author: Maro Ohanian